Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia

Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable side effect profile, and its self-administration at h...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosmas, Constantine E, Silverio, Delia, Ovalle, Julio, Montan, Peter D, Guzman, Eliscer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214408/
https://www.ncbi.nlm.nih.gov/pubmed/30464416
http://dx.doi.org/10.2147/PPA.S149423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214408/
https://www.ncbi.nlm.nih.gov/pubmed/30464416
http://dx.doi.org/10.2147/PPA.S149423

Ejemplares similares